Table 3.

Discriminatory Power of cMyC at Different Thresholds

[cMyC]
	10 ng/L	87 ng/L	120 ng/L
Patients with chest pain for <60 min (n=321)
Sensitivity	94.3% (87%–98.6%)	40.7% (29.1%–52.3%)	33.3% (22.2%–44.7%)
Specificity	32.1% (26.8%–37.9%)	90.3% (86.6%–93.8%)	92.3% (88.8%–95.3%)
NPV	95.5% (90.7%–98.9%)	85.6% (81.1%–89.6%)	84.4% (79.7%–88.5%)
PPV	26.3% (21%–32%)	52.1% (37.8%–65.4%)	52.5% (37.5%–67.5%)
Patients with chest pain for 60 to 120 min (n=156)
Sensitivity	98.1% (93.9%–100%)	54.7% (41.5%–68.5%)	46.5% (33.3%–60.8%)
Specificity	22.8% (15%–31.3%)	92.7% (86.9%–96.9%)	92.7% (86.9%–96.9%)
NPV	96.4% (87.1%–100%)	80.9% (73.6%–87.2%)	78.3% (70.6%–84.9%)
PPV	38% (30.3%–46.3%)	78% (63.9%–89.8%)	75% (58.6%–88.5%)
Patients with chest pain for ≥120 min (n=249)
Sensitivity	100% (100%–100%)	73.5% (61.8%–84.6%)	61.2% (48.3%–75%)
Specificity	29.9% (23.8%–36.6%)	88.9% (84%–93%)	91.5% (87.3%–95.1%)
NPV	100% (100%–100%)	92.7% (88.6%–96.2%)	90% (85.5%–93.8%)
PPV	27.6% (21.1%–33.7%)	63.8% (51.2%–75.5%)	65.8% (52.2%–78.4%)

cMyC indicates cardiac myosin‐binding protein C; NPV, negative predictive value; PPV, positive predictive value.